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between LC and D95% and D98%, but a strong dependence on 
Dmean (p=0.0274) and EUD (p=0.0483) was noticed. 
Fig. 1. The correlation between loco-regional control and D95% 
(a), D98% (b), Dmean (c) and EUD (d). Values of D95%, D98%, Dmean 
and EUD are normalized to the prescribed dose. 
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Due to the small number of patients, multivariate analysis of 
correlation between LC and patients' clinical and dosimetric 
data was not possible, and further studies are needed to 
identify the most predictive variable. 
Conclusions: LC for HNC patients treated with SIB IMRT 
significantly correlates with pathology, stage and the use of 
concomitant chemotherapy.  Treatment plan dosimetric data 
such as Dmean and EUD appear to be useful predictors of LC for 
this group of patients. 
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Purpose/Objective: Locoregional inoperable recurrence of 
previously irradiated head and neck carcinoma (HNC) remain 
a therapeutic challenge. In our previous study, we combined 
re-RT with cetuximab, with the aim to inhibit epidermal 
growth factor receptor EGFR and consequently increase 
tumor radiosensitivity, but this therapeutic approach did not 
influence patient survival in the comparison to standard 
therapy. Hedgehog (HH) signaling pathway, which plays 
important role in embryogenesis, carcinogenesis und 
radioresistance, can mediate therapeutic resistance to EGFR 
targeted therapies. Itraconazole is well known antimicotic 
agent which inhibits HH signaling. In patients with advanced 
basal cell carcinoma, itraconazole inhibited this pathway and 
caused promising clinical response. We propose that 
inhibition of HH signaling with itraconazole will avoid 
development of resistance to cetuximab and that 
simultaneous inhibition of these two pathways which 
interfere with radioresistance may lead to better tumor 
response and consequently prolonged survival in patient with 
recurrent HNC treated with re-RT. 
Materials and Methods: Between March and November 2014, 
we reirradiated (59.4 Gy, 5 X 1.8 Gy/Week) 5 patients with 
inoperable, previously irradiated, recurrent HNC. Cetuximab 
was given initially at 400 mg/m2 two days prior to re-RT and 
weekly (250 mg/m2) thereafter. Patients were treated with 
first dose itraconazole (100 mg) two days prior to re-RT and 
continued to take this drug daily two weeks after finishing re-
RT.  
Results: Itroconazole did not increase toxicity of re-RT and 
cetuximab expecting for induction of acne-like skin rash. 3 
patients developed grade III and 1 grade II of this 
complication. Until now, three patients had a first follow-up 
investigation – two partial responses (1 patient with grade I 
and one with grade III skin rash) and 1 with grade III and one 
stable disease were documented. 
Conclusions: Promising antitumor responses were observed. 
To determine if this therapeutic strategy may influence 
survival in patients with recurrent HNC treated with re-RT, 
larger clinical studies are necessary.  
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Purpose/Objective: To evaluate the efficacy and toxicity in a 
group of patient with non-metastatic nasopharyngeal 
carcinoma (NPC) treated with a hypofractionated radiation 
therapy with or without chemotherpy. 
